Indexing molecules for their hERG liability

European Journal of Medicinal Chemistry

Volumn 65, Issue , 2013, Pages 304-314

  Rayan, Anwar ^a   Falah, Mizied ^c   Raiyn, Jamal ^a,b   Da'Adoosh, Beny ^d   Kadan, Sleman ^a   Zaid, Hilal ^a   Goldblum, Amiram ^d  

^a Baka El Garbiah   (Israel)

^b Al Qasemi Academic College   (Israel)

^c Galilee Society   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cardio toxicity; Computational chemistry; hERG; Iterative Stochastic Elimination (ISE); Structure activity relations

Indexed keywords

ACID CITRATE DEXTROSE; POTASSIUM CHANNEL HERG; ZINC;

AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CORRELATION COEFFICIENT; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HUMAN; IC 50; IN VITRO STUDY; MOLECULE; PREDICTION; QT PROLONGATION; STOCHASTIC MODEL;

EID: 84878403944     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.04.059     Document Type: Article

References (63)

1. M.C. Sanguinetti, M. Tristani-Firouzi, hERG potassium channels and cardiac arrhythmia, Nature 440 (2006) 463-469.
2. U. Ravens, E. Cerbai, Role of potassium currents in cardiac arrhythmias, Europace 10 (2008) 1133-1137.
3. M.J. Perrin, R.N. Subbiah, J.I. Vandenberg, A.P. Hill, Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction, Prog. Biophys. Mol. Biol. 98 (2008) 137-148.
4. R. Tabrizchi, Molecular mechanisms of adverse drug reactions in cardiac tissue, Handb. Exp. Pharmacol. (2010) 77-109.
5. M.R. Gralinski, The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development, J. Pharmacol. Toxicol. Methods 43 (2000) 91-99. (Pubitemid 32057031)
6. L. Wu, S.R. Archacki, T. Zhang, Q.K. Wang, Induction of high STAT1 expression in transgenic mice with LQTS and heart failure, Biochem. Biophys. Res. Commun. 358 (2007) 449-454. (Pubitemid 46778913)
7. M.R. Bowlby, R. Peri, H. Zhang, J. Dunlop, hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk, Curr. Drug Metab. 9 (2008) 965-970.
8. E. Raschi, V. Vasina, E. Poluzzi, F. De Ponti, The hERG K+ channel: target and antitarget strategies in drug development, Pharmacol. Res. 57 (2008) 181-195.
9. A.S. Farkas, S. Nattel, Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice, Drugs 70 (2010) 573-603.
10. J.C. Hancox, M.J. McPate, A. El Harchi, Y.H. Zhang, The hERG potassium channel and hERG screening for drug-induced torsades de pointes, Pharmacol. Ther. 119 (2008) 118-132.
11. http://www.qtdrugs.org/, http://www.qtdrugs.org/.
12. M. Recanatini, E. Poluzzi, M. Masetti, A. Cavalli, F. De Ponti, QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development, Med. Res. Rev. 25 (2005) 133-166. (Pubitemid 40299844)
13. K. Finlayson, H.J. Witchel, J. McCulloch, J. Sharkey, Acquired QT interval prolongation and HERG: implications for drug discovery and development, Eur. J. Pharmacol. 500 (2004) 129-142. (Pubitemid 39304003)
14. S. Durdagi, J. Subbotina, J. Lees-Miller, J. Guo, H.J. Duff, S.Y. Noskov, Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs, Curr. Med. Chem. 17 (2011) 3514-3532.
15. F. De Ponti, E. Poluzzi, N. Montanaro, QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience, Eur. J. Clin. Pharmacol. 56 (2000) 1-18. (Pubitemid 30317776)
16. T. Ferrer-Villada, J.F. Cordero-Morales, M. Arias, E. Ficker, D. Medovoy, E. Perozo, M. Tristani-Firouzi, Molecular coupling in the human ether-a-go-go-related (hERG) K+ channel inactivation pathway, J. Biol. Chem. (2011).
17. R. Towart, J.T. Linders, A.N. Hermans, J. Rohrbacher, H.J. van der Linde, M. Ercken, M. Cik, P. Roevens, A. Teisman, D.J. Gallacher, Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening? J. Pharmacol. Toxicol. Methods 60 (2009) 1-10.
18. M. Masetti, A. Cavalli, M. Recanatini, Modeling the hERG potassium channel in a phospholipid bilayer: molecular dynamics and drug docking studies, J. Comput. Chem. 29 (2008) 795-808. (Pubitemid 351364854)
19. M. Recanatini, A. Cavalli, M. Masetti, Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations, ChemMedChem 3 (2008) 523-535.
20. N.S. Moorthy, S.F. Sousa, M.J. Ramos, P.A. Fernandes, In silico-based structural analysis of arylthiophene derivatives for FTase inhibitory activity, hERG, and other toxic effects, J. Biomol. Screen. (2011).
21. S. Durdagi, H.J. Duff, S.Y. Noskov, Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain, J. Chem. Inf. Model. 51 (2011) 463-474.
22. G. Markiewicz-Loskot, E. Moric-Janiszewska, U. Mazurek, The risk of cardiac events and genotype-based management of LQTS patients, Ann. Noninvasive Electrocardiol. 14 (2009) 86-92.
23. J.B. Saenen, C.J. Vrints, Molecular aspects of the congenital and acquired long QT syndrome: clinical implications, J. Mol. Cell. Cardiol. 44 (2008) 633-646.
24. R. Brugada, K. Hong, R. Dumaine, J. Cordeiro, F. Gaita, M. Borggrefe, T.M. Menendez, J. Brugada, G.D. Pollevick, C. Wolpert, E. Burashnikov, K. Matsuo, Y.S. Wu, A. Guerchicoff, F. Bianchi, C. Giustetto, R. Schimpf, P. Brugada, C. Antzelevitch, Sudden death associated with short-QT syndrome linked to mutations in HERG, Circulation 109 (2004) 30-35. (Pubitemid 38056017)
25. K. Hayashi, M. Shimizu, H. Ino, M. Yamaguchi, H. Terai, N. Hoshi, H. Higashida, N. Terashima, Y. Uno, H. Kanaya, H. Mabuchi, Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG, Clin. Sci. (Lond.) 107 (2004) 175-182. (Pubitemid 39070934)
26. L. Crotti, G. Celano, F. Dagradi, P.J. Schwartz, Congenital long QT syndrome, Orphanet J. Rare Dis. 3 (2008) 18.
27. P. Hoffmann, B. Warner, Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends, J. Pharmacol. Toxicol. Methods 53 (2006) 87-105.
28. D.M. Roden, Drug-induced prolongation of the QT interval, N. Engl. J. Med. 350 (2004) 1013-1022. (Pubitemid 38269278)
29. S. Viskin, Long QT syndromes and torsade de pointes, Lancet 354 (1999) 1625-1633. (Pubitemid 29515963)
30. J. Tamargo, Drug-induced torsade de pointes: from molecular biology to bedside, Jpn. J. Pharmacol. 83 (2000) 1-19. (Pubitemid 30352651)
31. H. Choe, K.H. Nah, S.N. Lee, H.S. Lee, S.H. Jo, C.H. Leem, Y.J. Jang, A novel hypothesis for the binding mode of HERG channel blockers, Biochem. Biophys. Res. Commun. 344 (2006) 72-78.
32. E.P. Scholz, N. Niemer, D. Hassel, E. Zitron, H.F. Burgers, R. Bloehs, C. Seyler, D. Scherer, D. Thomas, S. Kathofer, H.A. Katus, W.A. Rottbauer, C.A. Karle, Biophysical properties of zebrafish ether-a-go-go related gene potassium channels, Biochem. Biophys. Res. Commun. 381 (2009) 159-164.
33. B. Darpo, T. Nebout, P.T. Sager, Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use E14 guideline, J. Clin. Pharmacol. 46 (2006) 498-507.
34. R.R. Shah, Drug-induced QT interval prolongation-regulatory guidance and perspectives on hERG channel studies, Novartis Found. Symp. 266 (2005) 251-280. discussion 280-255.
35. J.S. Mitcheson, hERG potassium channels and the structural basis of drug-induced arrhythmias, Chem. Res. Toxicol. 21 (2008) 1005-1010.
36. M. Deacon, D. Singleton, N. Szalkai, R. Pasieczny, C. Peacock, D. Price, J. Boyd, H. Boyd, J.V. Steidl-Nichols, C. Williams, Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade, J. Pharmacol. Toxicol. Methods 55 (2007) 238-247. (Pubitemid 46436518)
37. D. Fernandez, A. Ghanta, G.W. Kauffman, M.C. Sanguinetti, Physicochemical features of the HERG channel drug binding site, J. Biol. Chem. 279 (2004) 10120-10127. (Pubitemid 38372616)
38. A.M. Aronov, Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers, J. Med. Chem. 49 (2006) 6917-6921. (Pubitemid 44749757)
39. B.Y. Zhu, Z.J. Jia, P. Zhang, T. Su, W. Huang, E. Goldman, D. Tumas, V. Kadambi, P. Eddy, U. Sinha, R.M. Scarborough, Y. Song, Inhibitory effect of carboxylic acid group on hERG binding, Bioorg. Med. Chem. Lett. 16 (2006) 5507-5512. (Pubitemid 44415463)
40. Q. Li, F.S. Jorgensen, T. Oprea, S. Brunak, O. Taboureau, hERG classification model based on a combination of support vector machine method and GRIND descriptors, Mol. Pharm. 5 (2008) 117-127. (Pubitemid 351300041)
41. E. Raschi, L. Ceccarini, F. De Ponti, M. Recanatini, hERG-related drug toxicity and models for predicting hERG liability and QT prolongation, Expert Opin. Drug Metab. Toxicol. 5 (2009) 1005-1021.
42. M.R. Doddareddy, E.C. Klaasse, Shagufta, A.P. Ijzerman, A. Bender, Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases, ChemMedChem 5 (2010) 716-729.
43. F. Ruggiu, G. Marcou, A. Varnek, H. Dragos, ISIDA property-labelled fragment descriptors, Front. Biosci. 29 (2010) 855-868.
44. B.H. Su, M.Y. Shen, E.X. Esposito, A.J. Hop finger, Y.J. Tseng, In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage, J. Chem. Inf. Model. 50 (2010) 1304-1318.
45. C. Obiol-Pardo, J. Gomis-Tena, F. Sanz, J. Saiz, M. Pastor, A multiscale simulation system for the prediction of drug-induced cardiotoxicity, J. Chem. Inf. Model. 51 (2011) 483-492.
46. A. Rayan, D. Marcus, A. Goldblum, Predicting oral druglikeness by iterative stochastic elimination, J. Chem. Inf. Model. 50 (2010) 437-445.
47. X.L. Zhao, Z.P. Qi, C. Fang, M.H. Chen, Y.J. Lv, B.X. Li, B.F. Yang, HERG K+ channel blockade by the novel antiviral drug sophocarpine, Biol. Pharm. Bull. 31 (2008) 627-632. (Pubitemid 351500492)
48. Y.J. Kim, H.K. Hong, H.S. Lee, S.H. Moh, J.C. Park, S.H. Jo, H. Choe, Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration, J. Cardiovasc. Pharmacol. 52 (2008) 485-493.
49. S.H. Jo, H.K. Hong, S.H. Chong, K.H. Won, S.J. Jung, H. Choe, Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652, Eur. J. Pharmacol. 592 (2008) 19-25.
50. T. Toga, Y. Kohmura, R. Kawatsu, The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities, J. Pharmacol. Sci. 105 (2007) 207-210. (Pubitemid 350106811)
51. D. Thomas, B.C. Hammerling, K. Wu, A.B. Wimmer, E.K. Ficker, G.E. Kirsch, M.C. Kochan, B.A. Wible, E.P. Scholz, E. Zitron, S. Kathofer, V.A. Kreye, H.A. Katus, W. Schoels, C.A. Karle, J. Kiehn, Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action, Br. J. Pharmacol. 142 (2004) 485-494. (Pubitemid 38869862)
52. R. Dumaine, M.L. Roy, A.M. Brown, Blockade of HERG and Kv1.5 by ketoconazole, J. Pharmacol. Exp. Ther. 286 (1998) 727-735. (Pubitemid 29003462)
53. CCG, MOE: Molecular operating environment, Chemical computing group, http://www.chemcomp.com/, MOE: Molecular operating environment; Chemical computing group, 2009.
54. A. Rayan, A. Goldblum, Stochastic Method to Determine, In Silico, the Drug-like Character of Molecules. US 20070156343, Yissum, Hebrew University, 2005.
55. M. Glick, A. Rayan, A. Goldblum, A stochastic algorithm for global optimization and for best populations: a test case of side chains in proteins, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 703-708. (Pubitemid 34106574)
56. A. Rayan, E. Noy, D. Chema, A. Levitzki, A. Goldblum, Stochastic algorithm for kinase homology model construction, Curr. Med. Chem. 11 (2004) 675-692. (Pubitemid 38380043)
57. A. Rayan, H. Senderowitz, A. Goldblum, Exploring the conformational space of cyclic peptides by a stochastic search method, J. Mol. Graph Model. 22 (2004) 319-333. (Pubitemid 38510300)
58. O. Ursu, A. Rayan, A. Goldblum, T.I. Oprea, Understanding drug-likeness, WIREs Computational Mol. Sci. 1 (2011) 760-781.
59. B.W. Matthews, Comparison of the predicted and observed secondary structure of T4 phage lysozyme, Biochim. Biophys. Acta 405 (1975) 442-451.
60. M.Q. Zhang, B. Wilkinson, Drug discovery beyond the 'rule-of-five', Curr. Opin. Biotechnol. 18 (2007) 478-488.
61. A.L. Gill, M. Verdonk, R.G. Boyle, R. Taylor, A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development, Curr. Top. Med. Chem. 7 (2007) 1408-1422. (Pubitemid 47471238)
62. E. Muraglia, O. Kinzel, C. Gardelli, B. Crescenzi, M. Donghi, M. Ferrara, E. Nizi, F. Orvieto, G. Pescatore, R. Laufer, O. Gonzalez-Paz, A. Di Marco, F. Fiore, E. Monteagudo, M. Fonsi, P.J. Felock, M. Rowley, V. Summa, Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors, J. Med. Chem. 51 (2008) 861-874. (Pubitemid 351304695)
63. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 46 (2001) 3-26. (Pubitemid 33653411)